INV-311
The role of myeloperoxidase (MPO) in oxidative tissue damage has become an area of intense research within the last couple of years. Evidence has emerged that MPO-derived oxidants contribute to tissue damage and the initiation and propagation of acute and chronic vascular inflammatory disease. MPO has also been implicated in oxidative damage within the brain of stroke patients and in the kidneys. Circulating levels of MPO have been shown to be predictors of risks for major adverse cardiac events.
INV-311 has been shown to be an effective inhibitor of MPO in early in-vitro models. Due to the lack of currently available drugs as MPO inhibitors, InVasc hopes to find a partner for this opportunity that could assist in advancing the drug to an IND filing and human clinical trials.
First-in-class drug candidate for oxidative damage caused by acute vascular events
